UnknownNot Applicable

Characterization of the microVAScular Dysfunction in Covid-19 ARDS

France40 participantsStarted 2021-12-10

Plain-language summary

The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS. Secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with COVID-19 and non-COVID-19 ARDS, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ARDS patients with COVID-19 and non-COVID-19 ARDS, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with COVID-19 and non-COVID-19 ARDS.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age\> 18 years old * Invasive mechanical ventilation in place for less than 48 hours * Severe or moderate ARDS (defined according to the Berlin classification) * Virological confirmation by PCR of SARS-CoV-2 infection (ARDS COVID-19) * Lack of virological confirmation by PCR of SARS-CoV-2 infection (ARDS not linked to COVID-19) * Patient information Exclusion Criteria: * Massive pulmonary embolism * Chronic respiratory failure under long-term oxygen therapy * Dying patient

What they're measuring

Prognostic value of alveolar dead space

Timeframe: Up to 28 days

Trial details

NCT IDNCT05074758

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-09-10

Contact for this trial

Josephine Braun, PhD

01 44 84 17 38 josephine.braun@aphp.fr

View on ClinicalTrials.gov More ARDS, Human trials